SHANGHAI, Dec. 23, 2015 /PRNewswire/ -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that it did not issue a press release regarding Great Basin Scientific dated December 22 and posted on websites of news organizations. Statements in that release that the board of directors of WuXi AppTec had approved a resolution to acquire all of the outstanding shares of Great Basin Scientific are untrue.
WuXi AppTec is a private company, having completed its go-private transaction earlier in December 2015. Although it is WuXi's typical practice not to comment on its merger and acquisition activities, WuXi wishes to further clarify that it has had limited or no commercial interaction with or knowledge of the company and is not currently, nor was it previously, engaged in acquisition discussions with the company.
About WuXi AppTec
WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnolgy, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.
For more information, please contact:
Director of Corporate Communications
SOURCE WuXi AppTec